Literature DB >> 2476531

Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer.

S W Hansen1, S Helweg-Larsen, W Trojaborg.   

Abstract

Thirty patients treated for germ cell cancer with six cycles of cisplatin, vinblastine, and bleomycin participated in a follow-up examination of neurotoxicity 49 to 106 months after treatment. Of these, 22 patients (73%) had sensory loss; half of them complained of paresthesias. The vibration perception threshold was increased in 24 patients (80%). Auditory stimulation revealed a normal latency of the first component of the brain stem-evoked potentials Pl but an increased interpeak interval between this and Pv; reflecting a central conduction defect. Motor conduction velocity (CV) along the peroneal nerve was normal. The average sural nerve CV was decreased (P less than .01) and the sensory action potential amplitude was reduced (P less than .01). Warm perception threshold was increased in 10 patients (33%). Cortical-evoked potentials after tibial nerve stimulation had increased latencies in 29 patients (97%). The peripheral CV along the tibial nerve was slowed (P less than .01) in 19 patients, and the central conduction time from Th12 to cortex was prolonged in 15 patients (P less than .01). The changes in conduction along peripheral and central pathways after tibial nerve stimulation are compatible with a toxic effect on the sensory root ganglia causing a "dying back" axonal degeneration of central and peripheral nerve fibers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476531     DOI: 10.1200/JCO.1989.7.10.1457

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  23 in total

Review 1.  Comparative tolerability of chemotherapy regimens for germ cell cancer.

Authors:  S Culine; J P Droz
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.

Authors:  A Hovestadt; M E van der Burg; H B Verbiest; W L van Putten; C J Vecht
Journal:  J Neurol       Date:  1992-03       Impact factor: 4.849

3.  Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer.

Authors:  S W Hansen
Journal:  BMJ       Date:  1990-02-24

Review 4.  Treatments for astrocytic tumors in children: current and emerging strategies.

Authors:  Stanislaw R Burzynski
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.

Authors:  Mette Sprauten; Thomas H Darrah; Derick R Peterson; M Ellen Campbell; Robyn E Hannigan; Milada Cvancarova; Clair Beard; Hege S Haugnes; Sophie D Fosså; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

6.  Electric shock-like sensations in 42 cancer patients: clinical characteristics and distinct etiologies.

Authors:  A Lossos; T Siegal
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

7.  Effects of cisplatin and ORG.2766 in chick embryonic brain cell cultures.

Authors:  A Bruinink; F Birchler
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

Review 8.  Long-term complications of chemotherapy for germ cell tumours.

Authors:  Uzair B Chaudhary; Jason R Haldas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study.

Authors:  Daniela Matei; Anna M Miller; Patrick Monahan; David Gershenson; Qianqian Zhao; David Cella; Victoria L Champion; Stephen D Williams
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

10.  Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.

Authors:  Marianne Brydøy; Jan Oldenburg; Olbjørn Klepp; Roy M Bremnes; Erik A Wist; Tore Wentzel-Larsen; Erik R Hauge; Olav Dahl; Sophie D Fosså
Journal:  J Natl Cancer Inst       Date:  2009-12-16       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.